Versant Capital Management’s Tourmaline Bio TRML Stock Holding History

Versant Capital Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-600	Closed	-$28.7K	–	2739
2025 Q3	$28.7K	Hold	600	–	–	﹤0.01%	1368
2025 Q2	$9.59K	Hold	600	–	–	﹤0.01%	1907
2025 Q1	$9.13K	Buy	+600	New	+$9.62K	﹤0.01%	1768

Versant Capital Management's TRML Position: Q4 2025 in Review

Versant Capital Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 600 shares — an estimated $28.7K sold.

Versant Capital Management first reported a position in TRML in Q1 2025 and held it in 3 quarters. The position peaked at $28.7K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Versant Capital Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Versant Capital Management sold 600 Tourmaline Bio shares in Q4 2025, an estimated $28.7K.
Versant Capital Management first reported a position in Tourmaline Bio in Q1 2025 and held it in 3 quarters.
Versant Capital Management's Tourmaline Bio position peaked at $28.7K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Versant Capital Management's 13F filing for Q4 2025, filed 8 Jan 2026.